Comparison of Tacrolimus 0.1% and Clobetasol 0.05% in the Management of Symptomatic Oral Lichen Planus
NCT ID: NCT02744378
Last Updated: 2016-04-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
68 participants
INTERVENTIONAL
2014-06-30
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Topical Treatment With Clobetasol in Symptomatic Oral Lichen Planus.
NCT04364555
Tacrolimus Ointment in Oral Lichen Planus
NCT01544842
Study on Treatment for Patients With Symptomatic Oral Lichen Planus
NCT04718311
Evaluation of the Efficacy of 0.08% Tacrolimus Nanoencapsulated Aqueous Solution Spray Vs. 0.1% Free Tacrolimus Commercial Ointment in the Treatment of Oral Lichen Planus
NCT06591884
Treatment Protocols for Patients With Symptomatic Oral Lichen Planus
NCT04673916
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Clobetasol Group
clobetasol propionate (0.05%) cream
Clobetasol 0.05%
This group was randomly allocated to receive topical Clobetasol 0.05% for 3 consecutive weeks
Tacrolimus Group
tacrolimus (0.1%) cream
Tacrolimus 0.1%
This group was randomly allocated to receive topical Tacrolimus 0.1% for 3 consecutive weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tacrolimus 0.1%
This group was randomly allocated to receive topical Tacrolimus 0.1% for 3 consecutive weeks
Clobetasol 0.05%
This group was randomly allocated to receive topical Clobetasol 0.05% for 3 consecutive weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Symptomatic
Exclusion Criteria
* contraindication for medications use such as a history of allergy to either corticosteroids/ tacrolimus
* immunosuppression, or pregnant / lactating females
* lichenoid reactions either drug induced or due to dental amalgam
* diabetes mellitus and on oral hypoglycemic drugs
* systemic involvement such as concurrent skin/genital lesions
20 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Peradeniya
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. P.V.K.S Hettiarachchi
Dr
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RG/2013/08/D
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.